---
title: "GT Biopharma, Inc. (GTBP.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/GTBP.US.md"
symbol: "GTBP.US"
name: "GT Biopharma, Inc."
industry: "Biotechnology"
datetime: "2026-05-20T09:36:08.720Z"
locales:
  - [en](https://longbridge.com/en/quote/GTBP.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/GTBP.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/GTBP.US.md)
---

# GT Biopharma, Inc. (GTBP.US)

## Company Overview

GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumors;and GTB-7550, a pre-clinical stage product candidate in development for the treatment of lupus and other autoimmune disorders. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.gtbiopharma.com](https://www.gtbiopharma.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.37 | 117 | - | - | - |
| PB | 1.79 | 172 | 2.65 | 2.15 | 0.95 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-15T04:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 0.43 |
| Highest Target | 3.00 |
| Lowest Target | 3.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/GTBP.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/GTBP.US/norm.md)
- [Related News](https://longbridge.com/en/quote/GTBP.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/GTBP.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**